Adenocarcinoma clinical trials

Explore recruiting adenocarcinoma clinical trials.

Recruiting adenocarcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Adenocarcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma with KRAS p.G12C mutation

France, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first line gemcitabine-based chemotherapy

Spain, Italy, Netherlands, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Master Protocol for an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants with Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)

Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Open-Label, Randomized Study to Assess the Efficacy and Safety of Zolbetuximab (IMAB362) in Combination with Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Ireland, Spain, Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase Ib-II, non-randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with modFOLFIRINOX for front-line treatment of metastatic pancreatic adenocarcinoma

Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A randomized, phase IIb study of adjuvant durvalumab (MEDI4736) plus regorafenib vs untreated control in stage IV colorectal cancer patients with no evidence of disease (NED): VIVA trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Adenocarcinoma trials by city

Adenocarcinoma in Toronto Adenocarcinoma in Vancouver Adenocarcinoma in Montreal Adenocarcinoma in Calgary Adenocarcinoma in Edmonton Adenocarcinoma in Ottawa Adenocarcinoma in Winnipeg Adenocarcinoma in Quebec City Adenocarcinoma in Hamilton Adenocarcinoma in Kitchener Adenocarcinoma in London Adenocarcinoma in Halifax Adenocarcinoma in New York Adenocarcinoma in Los Angeles Adenocarcinoma in Chicago Adenocarcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease